[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587535":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":57,"collaborators":20,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":20,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":20,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Participants receive RFA intervention for thyroid nodule.",[13],"Procedure: Radiofrequency ablation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Radiofrequency ablation","Radiofrequency energy is delivered to the thyroid nodule via the medical device. This device is a system consisting of 3 main components:\n\n1. VIVA combo RF system (generator and pump)\n2. single foot switch\n3. electrode (5mm, 7mm, 10mm, or adjustable).",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Jesse D Pasternak, MD, MPH","University Health Network (UHN) Toronto","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Jesse Pasternak","CONTACT","(416) 340-4792","jesse.pasternak@uhn.ca",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":34},"Emily Saso","emily.saso@uhn.ca",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University Health Network","RECRUITING","Toronto","Ontario","M5G2C4","Canada","CA",{"type":45,"coordinates":46},"Point",[47,48],-79.39864,43.70643,{"lat":48,"lon":47},[51,54,56],{"name":52,"role":29,"phone":30,"phoneExt":20,"email":53},"Ilhaan Abdulle","ilhaan.abdulle@uhn.ca",{"name":33,"role":29,"phone":55,"phoneExt":20,"email":34},"(613) 854-4420",{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":28,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator","100587535","the-safety-and-feasibility-of-radiofrequency-ablation-to-treat-low-risk-thyroid-cancer-100587535",false,"NCT06929650","The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer","Thermo-Ablation With Radiofrequency Medical Technologies to Treat Thyroid Cancers","Inclusion Criteria:\n\n1\\. Patients with:\n\n* Nodule less than or equal to 2cm in size\n\n  a. Specifically: Bethesda 5\u002F6\n* Their age is ≥18 years and ≤100 years\n* Able to provide written consent\n* Able to attend required follow-ups as per the protocol\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Pregnant women\n* Any concern for invasive or metastatic thyroid cancer\n* Previously treated for thyroid cancer",true,"ALL","18 Years","100 Years",{"count":71,"type":72},40,"ESTIMATED","INTERVENTIONAL",[75],"NA","The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is:\n\n• What is the feasibility of RFA use for low-risk thyroid cancers (≤2 cm)?\n\nParticipants will undergo a set of pre-procedural scans of the target thyroid nodule and undergo the RFA procedure\u002Fintervention. Then, participants will partake in three follow-up appointments at 4 weeks, 6 months, and 12 months post-procedure as per standard of care.",[78,79],"Thyroid Nodule","Thyroid Cancer",[81,82,83,84],"Radiofrequency Ablation","Feasibility","Adverse Event","Thyroid nodule","2025-04-08",{"date":87,"type":88},"2025-04-16","ACTUAL",{"date":90,"type":88},"2023-04-20",{"date":92,"type":72},"2025-12-31",{"name":5,"class":6},1]